Editorial Staff

MA Health Insurers Have Made Good Progress in Price Transparency, But Significant Work Remains

/in , , , , , /by Editorial Staff
Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Read press coverage of this report in the Boston Business Journal and State House News Service.

Tools are more user friendly and cover growing number of procedures, but still used by just a small fraction of potential market

BOSTON – A Pioneer Institute study finds some significant improvements in the online cost estimator tools created by Massachusetts’ three largest health insurers, but there is much still to be done for the carriers to maximize the opportunity price transparency represents.

Download Report

Online cost estimator tools give consumers/plan members online information about a range of information for outpatient and many inpatient procedures. These tools display the amount that has to be paid by consumers to any particular provider, how much the plan pays the provider, and information about provider quality.  Consumers can compare several providers at the same time.

“Price transparency can help initiate reforms that reduce healthcare costs and allow market forces to drive patients to lower-cost, higher-value providers,” said Barbara Anthony, primary author of MA Health Insurers Have Improved Their Consumer Price Transparency Efforts, But Significant Work Remains.

A 2012 state law required health insurers to develop online cost estimator tools by October 2014.  In 2015, the advocacy group Health Care for All (HCFA) assessed the tools developed by Blue Cross Blue Shield (BCBS), Harvard Pilgrim Health Care (HPHC), and Tufts Health Plan, which together controlled nearly four-fifths of the state health insurance market.  HCFA gave each a grade of “C.”

The same law also requires hospitals and doctors to provide consumers with prices of services upon request. Previous Pioneer studies showed very poor compliance by Massachusetts providers with the Commonwealth’s transparency law.

As a follow up to the HCFA study, in late 2017, Pioneer assessed the same carriers’ performance and found their tools more user friendly.  They cover between 700 and 1600 procedures, a vast improvement over the initial numbers of procedures available in 2015.  Importantly, Pioneer found that all three carriers are embracing incentive/reward programs to attract workers at entities with 250 or more employees to lower-cost, high-value providers.  Pioneer’s study was done with the full cooperation of the carriers.

Under incentive/rewards programs, employees are rewarded by either small or no co-payments or cash rewards from $25 to several hundreds of dollars for choosing lower-cost, high-value providers such as outpatient surgical centers rather than a hospital outpatient clinic. HPHC has developed a program called SaveOn that makes it easier for members to switch providers to avoid co-pays or earn cash rewards.  BCBS has aggressively embraced and marketed cash incentive programs to both businesses and municipalities.  In all cases, the plans say they are embracing incentive programs and transparency to compete with large national carriers here and regionally.

Both the HPHC’s and THP’s tools are a significant improvement over their initial cost estimator tools.   After their common vendor pulled out of the market, the carriers had to entirely revamp their tools. The results are new, easy-to-navigate online tools which display out-of-pocket consumer costs, the remaining deductible, and quality metrics.

Since 2015, BCBS has made several improvements that make its product more consumer friendly: by simply changing the name of its tool from “Find a Doc” to “Find a Doc and Estimate Costs,” by making the tool much more prominent on its website, and clearly showing both out-of-pocket costs and remaining deductibles. BCBS also has an improved website for consumers.

Despite significant progress, however, deficiencies remain. The carriers had about 297,000 aggregate inquiries on their cost estimator tools from early 2014 through 2017, compared to a potential market of at least three million people that the three carriers cover.

“The number of aggregate inquiries shows that carriers still have a lot of work ahead to achieve price transparency’s potential to rein in healthcare costs,” said Pioneer Institute Executive Director Jim Stergios.

In 2015, Massachusetts’ median annual household income was around $70,000 and the average family in the Commonwealth spent about $20,000 on premiums and cost sharing.  “These figures show that transparency in healthcare is important to the budgets of Massachusetts families,” added Stergios.

HPHC’s and Tufts’ estimator tools still don’t provide cost data on many behavioral health procedures.

The BCBS site is compatible with online translation tools, but none of the carriers’ cost estimator tools are readily available in a language other than English.

Anthony noted that “While state government has not provided any compliance leadership for consumer price transparency, now, after overcoming resistance and a lack of support, the market is waking up to the potential benefits of price transparency and incentive programs.”

Comments from Harvard Pilgrim Health Care, Blue Cross Blue Shield and Tufts Health Plan:

“In a rapidly changing healthcare environment, providing consumers with transparency around cost and quality information is important and will help them make informed healthcare choices,” said Harvard Pilgrim President and CEO Eric Schultz. “We at Harvard Pilgrim have long been committed to promoting the value of transparency, and we are pleased to see that Pioneer Institute continues to keep a public focus on the issue. We were happy to work with them on this report.”

“Blue Cross is pleased that the Pioneer report acknowledges our ongoing commitment to providing our members with state-of-the-art tools to make informed decisions about the cost and quality of their healthcare.  Members who understand their benefits – those who aren’t surprised by bills and feel empowered – are much more likely to be satisfied members and engaged patients. I thank Pioneer Institute for their continued focus on this issue,” said Andrew Dreyfus, BCBS President and CEO.

“Transparency is essential among all stakeholders in healthcare to ensure that customers and employer groups can make informed healthcare decisions,” said Tom Croswell, President and CEO at Tufts Health Plan. “[O]ur new, easy-to-use tool enables members to not only find high-quality, high-value providers in their area, but also see their potential costs from the beginning to the end of a procedure. The new tool is simpler and far surpasses the capabilities of the first generation of transparency tools. We applaud Pioneer Institute’s work on keeping this important issue at the forefront.”

About the Authors

Barbara Anthony, a lawyer, is a senior fellow in healthcare at Pioneer Institute focusing on healthcare price and quality transparency.  She is also an associate at the Harvard Kennedy School’s Center for Business and Government.  She served as Massachusetts Undersecretary for Consumer Affairs and Business Regulation from 2009 to 2015.

Scott Haller graduated from Northeastern University with a Bachelor’s Degree in Political Science. He started working at Pioneer Institute through the Northeastern’s Co-op Program and continues now as the Lovett C. Peters Fellow in Healthcare. He previously worked at the Office of the Inspector General.

About Pioneer

Pioneer Institute is an independent, non-partisan, privately funded research organization that seeks to improve the quality of life in Massachusetts through civic discourse and intellectually rigorous, data-driven public policy solutions based on free market principles, individual liberty and responsibility, and the ideal of effective, limited and accountable government.

Get Updates On Our Healthcare Research and Events!

Related Posts

Pioneer Institute: 340B Hospitals Does Not Necessarily Translate to Charity Care

Review of Becker’s List of Health Systems with Strong Finances…

Average Weekly Wages of Healthcare Workers Across a Decade

From 2012-22 the healthcare and social assistance sector has seen the smallest growth in average weekly wages of any large industry in Massachusetts. This potentially has dire consequences on the employment crisis that this industry already faces.

Do No Harm to the Health Policy Commission

With only weeks left in the Massachusetts legislative calendar,…

New Online Tool Tracks MA Hospital Revenue from Commercial Sources

A new online tool from Pioneer Institute shows a gradual increase in non-commercial (public payer) revenue at Massachusetts hospitals and also reveals a strong relationship between the hospitals with the highest commercial revenue and those with the highest relative prices.

Study Finds Obstacles to Search for Opioid Substitute

Inflation Reduction Act price controls on the category of…

Transformative Medical Therapy Will Require New Cost-Benefit and Pricing Models

Current regulations increase development and manufacturing costs,…

Genetic Therapy Revolution: Benefits and Barriers for Medicine’s New Horizon

Joe Selvaggi talks with neurobiologist and writer Dr. Anne Sydor about the potential for gene therapy to address deadly and debilitating diseases and how current health care models must adapt to encourage this nascent technology.

Boston Children’s, MGH Among Massachusetts Hospitals with Highest Relative Commercial Prices

Pioneer Institute's new tool, the Massachusetts Hospital Relative Price Tracker, displays relative price and facilitates relative price comparisons among hospitals. The average price among all hospitals will have a relative price of 1.0. A relative price of 1.5 means that a hospital charges 50 percent higher than the average of all Massachusetts hospitals. Similarly, a relative price of 0.84 means that a hospital’s prices are 16 percent below average. Relative price data is collected and reported by the Commonwealth’s Center for Health Information and Analysis (CHIA) and is an aggregate measure used to evaluate price variations among different hospitals. It is recalculated annually based on data collected from commercial payers and includes information on private commercial insurance and commercially managed public insurance products such as Medicare Advantage and Medicaid Managed Organizations/Accountable Care Partnership Plans.

Middlemen Pushing Up Retail Costs of Drugs

The reality is that non-price factors, including several players, are causing net prices to decline and retail prices to increase. Those players include employers, health plans, and pharmacy benefit managers (PBMs), all of whom have continuously circumvented the system through loopholes and complicated systems of reimbursement that tend to hurt patients

Telehealth Progress Slowed in 2023

A new report by Cicero Institute, Pioneer Institute, and Reason Foundation reveals worrying stagnation in state-level telehealth expansion efforts in 2023, with only a few exceptions. Progress made during the pandemic is being lost even as provider shortages worsen, raising concerns about patients’ access to care.

‘High’ U.S. Drug Prices Mask Freeloading by Other Nations

The drug company’s choice is to walk away from millions in revenue from a given country and deny their people a lifesaving drug, or swallow hard and accept an unfair price that is nowhere near the drug’s value. For the sake of shareholders and patients, drug companies typically accept the unfair price and devote the revenue to offsetting their previous investments. In short, other nations are freeloading off of American R&D.

Drug Discount Distortions: How Middlemen Increase Costs and Reduce Access

Joe Selvaggi talks with Drs. Bill Smith and Robert Popovian about how the complex system of rebates from drug companies to insurance firms serve to increase costs and reduce access for patients.

Opinion: Legislature should act on bill to limit out-of-pocket drug costs

S. 609, a bill that would limit out-of-pocket costs for patients paying for prescription drugs, is a clear step in the right direction. Massachusetts should join 16 other states that have passed similar bills to protect patients.

Opinion: Drug patents aren’t a ‘necessary evil.’ They save lives.

Drug patents are one of the most important public policy innovations in all of human history, and a boon to patients awaiting cures. Inventions only come when inventors are rewarded, not punished. Patents are not a “necessary evil.”

Study: High List Prices and Deep Discounts for Prescription Drugs Hurt Poor and Sick Patients

A new Pioneer Institute study illustrates how the current system of drug pricing and discounts leads to patients with challenging diseases being charged huge out-of-pocket sums to keep other premiums low, effectively imposing financial penalties on the sick to protect the healthy and wealthy.

Out-of-Pocket Pirates: Spotlight on Accumulator & Maximizer Programs

A new white paper, "Out-of-Pocket Pirates: Pharmacy Benefit Managers (PBMs) and the Confiscation of Copayment Assistance Programs," examines how the way these programs are implemented is having negative impacts on patients living with serious diseases.

Study: Massachusetts Should Join 45 States and Allow Prescribers to Dispense Medications

A Pioneer Institute study shows that middlemen—commercial pharmacies and pharmacy benefit managers—add substantial costs over wholesale prices. Allowing prescribers to dispense routine drugs would save consumers money without compromising safety.

A Federal Drug Discount Program for the Wealthy

The combination of legal disputes, a growing data repository and investigative reports have necessarily put the 340B Drug Pricing Program under the microscope. Combined with the fact that the policy lacks transparency, 340B has spiraled out of control to the point that no policymaker can ignore the need to look closer.